Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

whitePaper | October 15, 2022

Because vitamin D receptors are present in most cells in the body, its active form has potent effects on the growth and differentiation of many types of cells, meaning that vitamin D

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

whitePaper | May 26, 2022

The medical device and pharmaceutical industries each share in a mission to improve health outcomes, from prevention to intervention. As a result of this shared mission, integration and overlap between these two industries has been taking place for decades.